Boston Scientific (BSX) posted an increase in second-quarter earnings and sales on the back of growing demand for its heart devices.
The medical device maker recorded adjusted earnings per share (EPS) of $0.62, with revenue jumping 14.5% year-over-year to $4.12 billion. Both beat the consensus estimate of analysts surveyed by Visible Alpha.
More than half of the company’s revenue came from sales of cardiovascular products, which rose 17.8% to $2.64 billion. Medical/Surgical unit sales were 9% higher at $1.48 billion.
Regionally, the company’s U.S. sales rose the most, up 16.9% to $2.47 billion.
Boston Scientific raised its full-year adjusted EPS forecast to a range of $2.38 to $2.42 from its previous outlook of $2.29 to $2.34. It sees revenue growth of 13.5% to 14.5%, up from 11.0% to 13.0%.
Boston Scientific shares were down 2.2% to $76.79 as of noon ET Wednesday, one day after they set a new record closing high of $78.58.